Immune checkpoint inhibitor (ICI) treatment reduced levels of estrogen and important heart-protective proteins, researchers reported in the Nov. 2, 2022, online edition of Science Translational Medicine. Hormone therapies could target this endocrine-cardiac-immune pathway and mitigate myocarditis risk without affecting treatment responses.